Literature DB >> 17306729

Client and counselor attitudes toward the use of medications for treatment of opioid dependence.

Traci Rieckmann1, Marilyn Daley, Bret E Fuller, Cindy P Thomas, Dennis McCarty.   

Abstract

Attitudes, perceived social norms, and intentions were assessed for 376 counselors and 1,083 clients from outpatient, methadone, and residential drug treatment programs regarding four medications used to treat opiate dependence: methadone, buprenorphine, clonidine, and ibogaine. Attitudes, social norms, and intentions to use varied by treatment modality. Methadone clients and counselors had more positive attitudes toward the use of methadone, whereas their counterparts in residential and outpatient settings had neutral or negative assessments. Across modalities, attitudes, perceived social norms, and intentions toward the use of buprenorphine were relatively neutral. Assessments of clonidine and ibogaine were negative for clients and counselors in all settings. Social normative influences were dominant across settings and medications in determining counselor and client intentions to use medications, suggesting that perceptions about beliefs of peers may play a critical role in use of medications to treat opiate dependence.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17306729      PMCID: PMC2847884          DOI: 10.1016/j.jsat.2006.09.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  19 in total

1.  Staff beliefs about addiction treatment.

Authors:  R F Forman; G Bovasso; G Woody
Journal:  J Subst Abuse Treat       Date:  2001-07

Review 2.  Drug therapy for alcohol dependence.

Authors:  R M Swift
Journal:  N Engl J Med       Date:  1999-05-13       Impact factor: 91.245

Review 3.  The theory of planned behavior: a review of its applications to health-related behaviors.

Authors:  G Godin; G Kok
Journal:  Am J Health Promot       Date:  1996 Nov-Dec

4.  Attitudes and beliefs of staff working in methadone maintenance clinics.

Authors:  J R Caplehorn; L Irwig; J B Saunders
Journal:  Subst Use Misuse       Date:  1996-03       Impact factor: 2.164

5.  Behavioral science and public health: a necessary partnership for HIV prevention.

Authors:  M Fishbein; M Guinan
Journal:  Public Health Rep       Date:  1996       Impact factor: 2.792

6.  Dispelling the myths about addiction: strategies to increase understanding and strengthen research

Authors: 
Journal:  BMJ       Date:  1998-05-30

Review 7.  A range of research-based pharmacotherapies for addiction.

Authors:  C P O'Brien
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

8.  Pharmacological treatment of alcohol dependence: a review of the evidence.

Authors:  J C Garbutt; S L West; T S Carey; K N Lohr; F T Crews
Journal:  JAMA       Date:  1999-04-14       Impact factor: 56.272

9.  Normative and attitudinal control as moderating influences on marijuana use.

Authors:  W O Bearden; A G Woodside
Journal:  J Health Soc Behav       Date:  1978-06

10.  Buprenorphine for acute heroin detoxification: diffusion of research into practice.

Authors:  Anne E Kovas; Bentson H McFarland; Dennis J McCarty; Joshua F Boverman; James A Thayer
Journal:  J Subst Abuse Treat       Date:  2006-11-21
View more
  37 in total

1.  Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.

Authors:  Sarah A Savage; Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2011-08-09

2.  The substance abuse counseling workforce: education, preparation, and certification.

Authors:  Traci Rieckmann; Christiane Farentinos; Carrie J Tillotson; Jonathan Kocarnik; Dennis McCarty
Journal:  Subst Abus       Date:  2011-10       Impact factor: 3.716

3.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

4.  A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment.

Authors:  Traci R Rieckmann; Anne E Kovas; Bentson H McFarland; Amanda J Abraham
Journal:  J Subst Abuse Treat       Date:  2011-08-06

5.  Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.

Authors:  Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Emily Scherer; Lisa A Marsch
Journal:  J Subst Abuse Treat       Date:  2020-01-21

6.  Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.

Authors:  Marcus A Bachhuber; Pooja K Mehta; Laura J Faherty; Brendan Saloner
Journal:  Med Care       Date:  2017-12       Impact factor: 2.983

7.  Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida.

Authors:  Amanda Sharp; Melissa Carlson; Veronica Howell; Kathleen Moore; Zev Schuman-Olivier
Journal:  J Subst Abuse Treat       Date:  2020-12-11

8.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

9.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

10.  Staff attitudes and the associations with treatment organisation, clinical practices and outcomes in opioid maintenance treatment.

Authors:  Linn Gjersing; Helge Waal; John R M Caplehorn; Michael Gossop; Thomas Clausen
Journal:  BMC Health Serv Res       Date:  2010-07-06       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.